Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Share this content:
Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer.
Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer.

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with T790M-positive, advanced non-small cell lung cancer (NSCLC) who progress after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment, according to a study published in the Journal of Clinical Oncology.1

The phase 2 extension component of the multicenter, open-label, phase 1/2 AURA trial (ClinicalTrials.gov Identifier: NCT01802632) enrolled 201 patients with EGFR-TKI-pretreated T790M mutation-positive NSCLC, including those with asymptomatic, stable central nervous system metastases that did not require corticosteroids. All participants received oral osimertinib at a dose of 80 mg once daily.

Results showed that 62% (95% CI, 54-68) of the 198 evaluable patients achieved an objective response with a median duration of response of 15.2 months (95% CI, 11.3-not calculable) in responding patients. Ninety percent (95% CI, 85-94) achieved disease control.

Median progression-free survival was 12.3 months (95% CI, 9.5-13.8). Those who received osimertinib as second-line and third-line or more had a median progression-free survival of 11.0 months (95% CI, 6.7-not calculable) and 12.4 months (95% CI, 9.5-15.5), respectively. Median overall survival was not reached (95% CI, 16.4-not calculable).

The most common adverse events potentially related to osimertinib were diarrhea in 43% and rash in 40%. Eight patients developed interstitial lung disease, including 3 fatal cases.

RELATED: NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

Osimertinib is an irreversible EGFR-TKI selective for both EGFR-TKI sensitizing mutations and T790M resistance mutations. It is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC who progress on or after EGFR-TKI therapy.

Reference

  1. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017 Feb 21. doi: 10.1200/JCO.2016.70.3223 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters